678 related articles for article (PubMed ID: 24837480)
1. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis.
Min Q; Molina L; Li J; Adebayo Michael AO; Russell JO; Preziosi ME; Singh S; Poddar M; Matz-Soja M; Ranganathan S; Bell AW; Gebhardt R; Gaunitz F; Yu J; Tao J; Monga SP
Am J Pathol; 2019 May; 189(5):1091-1104. PubMed ID: 30794807
[TBL] [Abstract][Full Text] [Related]
3. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
6. CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X; Kiss A; Schaff Z; Evert K; Zhang Y; Zhong S; Wang J; Evert M; Calvisi DF; Chen X
Pediatr Blood Cancer; 2020 May; 67(5):e28221. PubMed ID: 32124532
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
9. Hippo/YAP, β-catenin, and the cancer cell: a "ménage à trois" in hepatoblastoma.
Sylvester KG; Colnot S
Gastroenterology; 2014 Sep; 147(3):562-5. PubMed ID: 25072176
[No Abstract] [Full Text] [Related]
10. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.
Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW
Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833
[TBL] [Abstract][Full Text] [Related]
11. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
[TBL] [Abstract][Full Text] [Related]
12. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
13. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
Guo C; Wang X; Liang L
Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of Hippo kinase signalling in human hepatic malignancies.
Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
[TBL] [Abstract][Full Text] [Related]
16. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S; Zhang J; Evert K; Li X; Liu P; Kiss A; Schaff Z; Ament C; Zhang Y; Serra M; Evert M; Chen N; Xu F; Chen X; Tao J; Calvisi DF; Cigliano A
Am J Pathol; 2020 Jul; 190(7):1397-1413. PubMed ID: 32283103
[TBL] [Abstract][Full Text] [Related]
17. YAP1 negatively regulates chondrocyte differentiation partly by activating the β-catenin signaling pathway.
Yang B; Sun H; Song F; Yu M; Wu Y; Wang J
Int J Biochem Cell Biol; 2017 Jun; 87():104-113. PubMed ID: 28438716
[TBL] [Abstract][Full Text] [Related]
18. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma.
Fan X; Ma X; Cui L; Dang S; Qu J; Zhang J; Wang X; Mao Z
Oncotarget; 2016 Dec; 7(49):80404-80414. PubMed ID: 27829235
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
[TBL] [Abstract][Full Text] [Related]
20. KDM1A drives hepatoblastoma progression by activating the Wnt/β-catenin pathway through inhibition of DKK3 transcription.
Ji C; Chen L; Yuan M; Xie W; Sheng X; Yin Q
Tissue Cell; 2023 Apr; 81():101989. PubMed ID: 36642006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
